No price history available.
Key financial summary
Financials in ARS| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ARSm | 6,181 | 32,366 | 57,518 | 39,028 | 91,794 | 126,726 | N/A | N/A |
| Operating profit | ARSm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ARSm | 734 | 1,152 | 509 | -10,851 | 23,845 | 3,088 | N/A | N/A |
| EPS reported | ARS | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ARS | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ARS | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ARS | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ARSm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ARSm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ARSm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ARS | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ARS | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in ARS| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Laboratorios Richmond S.A.C.I.F. is a pharmaceutical firm focused on the development and production of a diverse range of medicinal products. Their extensive portfolio includes antiretroviral treatments for human immunodeficiency virus (HIV), as well as therapies for oncology and oncohematology conditions. The company also supplies various cardiometabolic medications, such as those for blood pressure reduction, cholesterol management, platelet aggregation inhibition, and blood sugar control. Additionally, they produce neurological and psychiatric drugs, covering analgesics, antipsychotics, antidepressants, anti-dementia agents, antiepileptics, hypnotics, and treatments for multiple sclerosis. These pharmaceutical offerings are distributed across Latin America, Africa, Asia, and the Middle East. Founded in 1935, Laboratorios Richmond S.A.C.I.F. is headquartered in Buenos Aires, Argentina.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Laboratorios Richmond S.A.C.I.F. (RICH.BA)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Laboratorios Richmond S.A.C.I.F. is a pharmaceutical firm focused on the development and production of a diverse range of medicinal products. Their extensive portfolio includes antiretroviral treatments for human immunodeficiency virus (HIV), as well as therapies for oncology and oncohematology conditions. The company also supplies various cardiometabolic medications, such as those for blood pressure reduction, cholesterol management, platelet aggregation inhibition, and blood sugar control. Additionally, they produce neurological and psychiatric drugs, covering analgesics, antipsychotics, antidepressants, anti-dementia agents, antiepileptics, hypnotics, and treatments for multiple sclerosis. These pharmaceutical offerings are distributed across Latin America, Africa, Asia, and the Middle East. Founded in 1935, Laboratorios Richmond S.A.C.I.F. is headquartered in Buenos Aires, Argentina.